Tango Therapeutics, Inc. (TNGX), headquartered in Cambridge, Massachusetts, is devoted to unraveling cancer's complexity and overcoming its resistance to treatment. This biotechnology company specializes in pioneering the discovery, development, and commercialization of innovative medicines that can improve and potentially prolong the lives of people suffering from cancer. Tango Therapeutics is driven by its purpose of altering the paradigm of cancer therapies to revolutionize patient care.
Founded in 2017 by leading scientists from renowned science and research entities, the company is primarily focused on creating medicines that exploit cancer's vulnerabilities. Tango Therapeutics' uniqueness lies in its proprietary research platform that leverages advances in DNA sequencing and CRISPR-based functional genomics to uncover genetically validated therapeutic targets.
Through this platform, the company aims to create superior, more precise, and individualized treatments for patients with a variety of cancer types. The company has meticulously integrated drug discovery capabilities to help accelerate the development and launch of their first program into clinical trials.
Tango Therapeutics is presently focused on developing targeted therapies for patients suffering from genetically defined cancers. They maintain a patient-centric approach, leaning on genetic data to design treatments that maximize effectiveness and minimize side effects. Their pipeline includes potential solutions for various types of cancer, including BRCA-1 breast cancer, CDK12 prostate cancer, and others still in the early phases of discovery and development.
Tango is unique due to its “synthetic lethality” method, a technique that detects and utilizes the interactions between pairs of genes in which the defect or disorder in one gene is harmless unless a corresponding defect occurs in the other gene. This approach offers the potential for targeted cancer therapies that could outperform traditional methods.
Tango Therapeutics' pioneering work in synthetic lethality and genetic vulnerabilities has attracted significant interest and support from high-profile institutional investors and industry partners. It's financed by Third Rock Ventures, Boxer Capital, and Casdin Capital, among others.
Tango Therapeutics, Inc. exemplifies how the integration of cutting-edge technology and a deep understanding of genomics can produce pioneering remedies to some of the most challenging health problems. With a mission built on science, innovation, and determination, this young biotech company shows immense promise in ushering in a new era of personalized cancer treatment.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Tango Therapeutics (TNGX) shares dropped 16.4% after updated phase I/II study data for its pancreatic cancer treatment showed a reduced objective response rate (ORR) of 82%, down from 92%. Despite the fall, the data still indicated durable disease control with an 88% progression-free survival rate at nine months. The company also announced a strategic reprioritization of its R&D programs, including a 14% workforce reduction and discontinuation of certain preclinical activities.
Tango Therapeutics reported promising results from its Phase 1/2 trial of vopimetostat combined with daraxonrasib for MTAP-deleted, RAS-mutant metastatic pancreatic cancer, showing an 82% objective response rate in pretreated patients. The trial also demonstrated a 100% disease control rate and an 88% 9-month progression-free survival rate, with manageable safety at dose level 1. These findings suggest a significant clinical benefit for a challenging patient population.
Tango Therapeutics plans to initiate a global Phase III trial in the first half of 2027 for its combination treatment of vopimetostat and daraxonrasib in first-line MTAP-deleted metastatic pancreatic cancer, following promising early-stage results. The Phase I study showed an 82% confirmed objective response rate and 100% disease control rate in previously treated patients, with a manageable safety profile. The company is also exploring an accelerated approval pathway for second-line disease and expanding into MTAP wild-type pancreatic cancer.